The Flanders formula: inside a leading European biopharma hub

3 January 2023

Never has the importance of Flanders’ biopharmaceutical output to the international community been more obvious than it was during the COVID-19 crisis.

At the height of the pandemic, from January to June 2021, some 90% of the vaccines imported to the UK came from the Belgian region.

But in fact, Flanders has long been one of Europe’s leading biopharma hubs, with numerous major research and manufacturing sites. Figures show that its pharma sector has annual revenue in excess of 53 billion euros ($57 billion) and a workforce of 65,000, creating a 23.6 billion euros trade surplus.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK